Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372244 | 0.93 | ADRB2 (1.00) | ADRB2 | |
| SCHEMBL186048 | 0.93 | ADRB2 (1.00) | ADRB2 | |
| Bromide SCHEMBL1289957 | 0.92 | ADRB2 (1.00) | ADRB2 | |
| Bromide SCHEMBL523612 | 0.92 | ADRB2 (1.00) | ADRB2 | |
| Hydrochloric Acid SCHEMBL1320905 | 0.92 | ADRB2 (0.99) | ADRB2 | |
| Phosphoric Acid SCHEMBL1321143 | 0.91 | ADRB2 (0.96) | ADRB2 | |
| Sulfuric Acid SCHEMBL1322299 | 0.90 | ADRB2 (0.95) | ADRB2 | |
| SCHEMBL3592448 | 0.84 | ADRB2 (1.00) | ADRB2 | |
| SCHEMBL3590466 | 0.83 | ADRB2 (0.82) | ADRB2 | |
| Trifluoroacetic Acid SCHEMBL3584806 | 0.83 | ADRB2 (0.77) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058294-B2 | Of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide; asthma and chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-11-15 | — | — | US | disclosed |
| EP-2364704-A1 | Combination of beta-adrenoceptor agonist and corticosteroid | AstraZeneca AB (SE) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093813-A1 | Salts 668 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20080249145-A1 | Salts 668 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249145-A1 | Salts 668 | DNPEP, SCN8A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB2 57/4885 |
| US-20100093813-A1 | Salts 668 | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SCN8A, ELANE | ADRB2 102/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | ADRB2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.